Skip to main content
  • Register
  • Help
  • Contact us

Avenue Therapeutics Inc (ATXI) USD0.0001

Sell:$4.25 Buy:$4.30 Change: $0.05 (1.19%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.05 (1.19%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.05 (1.19%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing its product principally for use in the acute/intensive care hospital setting. The Company’s product candidate is intravenous (IV) Tramadol, for the treatment of moderate to moderately severe post-operative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Its Oral tramadol is marketed in the United States for moderate to moderately severe pain in adults. Its Parenteral tramadol formulations include IV, intramuscular (IM), and subcutaneous (SC) formulations. Tramadol is marketed in the United States under the trade name Ultram immediate release tablet. Ultracet is a combination product containing tramadol and acetaminophen, is also marketed in the United States.

Contact details

2 Gansevoort St Fl 9
United States
+1 (781) 6524500

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$70.34 million
Shares in issue:
16.75 million
United States
US dollar

Key personnel

  • Lindsay Rosenwald
    Executive Chairman of the Board
  • Lucy Lu
    President, Chief Executive Officer, Director
  • Joseph Vazzano
    Chief Financial Officer, Principal Financial Officer and Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.